BJDX · Bluejay Diagnostics, Inc.
AI read · Good for BJDX
The AI's read
Those completed steps move Bluejay closer to checking its test and preparing for sales. The added site may help the company get ready to supply customers. The patient review reports an 18% death rate over 28 days, but gives no comparison, so it does not show how well the test works. Validation and the FDA submission are still ahead. The $7.38 million is expected to cover operations through Q2 2027. The company has made useful progress, but this update does not settle later testing or funding needs.